183 related articles for article (PubMed ID: 10774589)
1. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.
Demeter LM; Meehan PM; Morse G; Fischl MA; Para M; Powderly W; Leedom J; Holden-Wiltse J; Greisberger C; Wood K; Timpone J; Wathen LK; Nevin T; Resnick L; Batts DH; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):135-44. PubMed ID: 9768622
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
Reichman RC; Morse GD; Demeter LM; Resnick L; Bassiakos Y; Fischl M; Para M; Powderly W; Leedom J; Greisberger C
J Infect Dis; 1995 Feb; 171(2):297-304. PubMed ID: 7531207
[TBL] [Abstract][Full Text] [Related]
4. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
[TBL] [Abstract][Full Text] [Related]
8. In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite.
Rosser LM; O'Donnell AM; Lee KM; Morse GD
Antiviral Res; 1994 Dec; 25(3-4):193-200. PubMed ID: 7535991
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
McDowell JA; Lou Y; Symonds WS; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2061-7. PubMed ID: 10898676
[TBL] [Abstract][Full Text] [Related]
10. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
[TBL] [Abstract][Full Text] [Related]
11. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
Fletcher CV; Anderson PL; Kakuda TN; Schacker TW; Henry K; Gross CR; Brundage RC
AIDS; 2002 Mar; 16(4):551-60. PubMed ID: 11872998
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients.
Been-Tiktak AM; Vrehen HM; Schneider MM; van der Feltz M; Branger T; Ward P; Cox SR; Harry JD; Borleffs JC
Antimicrob Agents Chemother; 1995 Mar; 39(3):602-7. PubMed ID: 7793859
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
14. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
Crutchley RD; Ma Q; Sulaiman A; Hochreitter J; Morse GD
J Pharm Pract; 2011 Apr; 24(2):216-22. PubMed ID: 21712217
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.
Bergshoeff AS; Fraaij PL; Verweij C; van Rossum AM; Verweel G; Hartwig NG; de Groot R; Burger DM
J Antimicrob Chemother; 2004 Dec; 54(6):1152-4. PubMed ID: 15537694
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
Antivir Ther; 2011; 16(4):499-504. PubMed ID: 21685537
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
[TBL] [Abstract][Full Text] [Related]
19. Absorption, distribution, metabolism, and excretion of atevirdine in the rat.
Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Schuette MR; Judy RW; Voorman RL; Maio SM; Slatter JG
Drug Metab Dispos; 1998 Oct; 26(10):1008-18. PubMed ID: 9763407
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
